# A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil

> **NCT07518121** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Diabete Type 2

## Interventions

- **DRUG:** Efsubaglutide Alfa Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07518121
- **Lead sponsor:** Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-10-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07518121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07518121, "A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07518121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*